Skip to search formSkip to main contentSkip to account menu

Amprenavir:ACnc:Pt:Ser/Plas:Qn

Known as: ????:?????:???:??/??:???, amprenavir:concentración arbitraria:punto en el tiempo:suero/plasma:cuantitativo, Amprenavir:Arbitraire concentratie:Moment:Serum of plasma:Kwantitatief 
National Institutes of Health

Related topics

Related topics

4 relations
ACncAmprenavirPlasSerum

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Amprenavir or Fosamprenavir plus Ritonavir in HIV Infection
Amprenavir is an HIV-1 protease inhibitor, the first in vitro activity studies of which were published in 1995. During in vivo… 
2012
2012
Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
2007
2007
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
OBJECTIVES The purpose of this study was to evaluate the steady-state pharmacokinetics of amprenavir and ritonavir in HIV… 
2003
2003
Steady-State Pharmacokinetics of Amprenavir Coadministered with Ritonavir in Human Immunodeficiency Virus Type 1-Infected Patients
ABSTRACT The protease inhibitor (PI) ritonavir is used as a strong inhibitor of cytochrome P450 3A4, which boosts the activities… 
2002
2002
Single-Dose Pharmacokinetics of Amprenavir Coadministered with Grapefruit Juice
ABSTRACT In this crossover study in 12 healthy volunteers, coadministration of amprenavir (1,200 mg; single dose) with grapefruit… 
2002
2002
Synthesis and antiviral activity of new anti-HIV amprenavir bioisosteres.
Starting from the chemical structure of the recent FDA-approved anti-HIV drug Amprenavir (Agenerase), a potent HIV-protease… 
Review
2002
Review
2002
Clinical Pharmacology and Pharmacokinetics of Amprenavir
OBJECTIVE: To review the pharmacokinetics, pharmacodynamics, drug interactions, and dosage and administration information of… 
Highly Cited
2001
Highly Cited
2001
Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing
ABSTRACT In a dose-ranging study of amprenavir (formerly 141W94), an inhibitor of the protease enzyme of human immunodeficiency… 
2000
2000
Amprenavir
SummaryAbstractThe virological/immunological efficacy of amprenavir-containing combination regimens has been evaluated in a small… 
1998
1998
Salvage therapy with Ritonavir-Saquinavir plus 2 nucleosides reverse transcriptase inhibitors in patients failing with Amprenavir-AZT-3TC
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)